GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocugen Inc (NAS:OCGN) » Definitions » Shiller PE Ratio

Ocugen (Ocugen) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocugen Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ocugen Shiller PE Ratio Historical Data

The historical data trend for Ocugen's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocugen Shiller PE Ratio Chart

Ocugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocugen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ocugen's Shiller PE Ratio

For the Biotechnology subindustry, Ocugen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocugen's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocugen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ocugen's Shiller PE Ratio falls into.



Ocugen Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ocugen's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ocugen's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.05/131.7762*131.7762
=-0.050

Current CPI (Mar. 2024) = 131.7762.

Ocugen Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -55.602 100.560 -72.863
201409 -66.549 100.428 -87.322
201412 101.998 99.070 135.671
201503 -35.999 99.621 -47.619
201506 -34.799 100.684 -45.545
201509 -36.599 100.392 -48.041
201512 -37.799 99.792 -49.914
201603 -35.999 100.470 -47.216
201606 -36.599 101.688 -47.428
201609 -41.999 101.861 -54.334
201612 -37.799 101.863 -48.899
201703 -16.200 102.862 -20.754
201706 -15.000 103.349 -19.126
201709 -13.800 104.136 -17.463
201712 -15.600 104.011 -19.764
201803 -31.199 105.290 -39.047
201806 -7.800 106.317 -9.668
201809 -14.400 106.507 -17.817
201812 -8.650 105.998 -10.754
201903 -7.200 107.251 -8.846
201906 -1.800 108.070 -2.195
201909 -3.550 108.329 -4.318
201912 0.235 108.420 0.286
202003 -0.070 108.902 -0.085
202006 -0.190 108.767 -0.230
202009 -0.070 109.815 -0.084
202012 -0.021 109.897 -0.025
202103 -0.040 111.754 -0.047
202106 -0.130 114.631 -0.149
202109 -0.050 115.734 -0.057
202112 -0.070 117.630 -0.078
202203 -0.090 121.301 -0.098
202206 -0.090 125.017 -0.095
202209 -0.100 125.227 -0.105
202212 -0.100 125.222 -0.105
202303 -0.080 127.348 -0.083
202306 -0.100 128.729 -0.102
202309 -0.060 129.860 -0.061
202312 -0.040 129.419 -0.041
202403 -0.050 131.776 -0.050

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ocugen  (NAS:OCGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ocugen Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ocugen's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocugen (Ocugen) Business Description

Traded in Other Exchanges
Address
11 Great Valley Parkway, Malvern, PA, USA, 19355
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Executives
Junge Zhang director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Quan Anh Vu officer: CFO/CBO 22616 ERWIN STREET, WOODLAND HILLS CA 91367
Shankar Musunuri director, officer: Chief Executive Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Arun Upadhyay officer: Chief Scientific Officer C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355
Ramesh Kumar director 375 PHEASANT RUN, NEWTOWN PA 18940
Kirsten Castillo director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Uday Kompella director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Marna C Whittington director 2959 BARLEY MILL ROAD, YORKLYN DE 19736
Jessica Crespo officer: CAO/SVP, Finance C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355
Sanjay Subramanian officer: Chief Financial Officer 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Manish Potti director C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355
Vijay Tammara officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Suha Taspolatoglu director 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Kelly Beck officer: Vice President 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355